Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
Psychedelic
emotion
insight
mediation
therapy
well-being
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
6
1
2022
medline:
4
3
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
As their name suggests, 'psychedelic' (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight The PIS is a six- to seven-item questionnaire that enquires about psychological insight Principal components analysis of PIS scores revealed a principal component explaining 73.57% of the variance, which displayed high internal consistency at multiple timepoints throughout the study (average Cronbach's α = 0.94). Criterion validity was confirmed using the global psychedelic survey study, and convergent validity was confirmed via the Therapeutic-Realizations Scale. Furthermore, PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being. The PIS is complementary to current subjective measures used in psychedelic studies, most of which are completed in relation to the acute experience. Insight - as measured by the PIS - was found to be a key mediator of long-term psychological outcomes following a psychedelic experience. Future research may investigate how insight varies throughout a psychedelic process, its underlying neurobiology and how it impacts behaviour and mental health.
Identifiants
pubmed: 34983255
doi: 10.1177/02698811211066709
pmc: PMC8801624
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-45Références
Front Psychol. 2018 Oct 12;9:1721
pubmed: 30369890
Psychiatry Res. 2019 Nov;281:112561
pubmed: 31521839
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
J Nerv Ment Dis. 1958 Dec;127(6):528-39
pubmed: 13621221
Psychopharmacology (Berl). 2020 Aug;237(8):2293-2304
pubmed: 32500212
J Clin Psychiatry. 2006 Nov;67(11):1735-40
pubmed: 17196053
J Psychopharmacol. 2016 Dec;30(12):1268-1278
pubmed: 27578767
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
J Psychopharmacol. 2008 Aug;22(6):603-20
pubmed: 18593734
Cell. 2020 Apr 2;181(1):24-28
pubmed: 32243793
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
Psychotherapy (Chic). 2016 Mar;53(1):105-16
pubmed: 26785358
J Psychopharmacol. 2021 Apr;35(4):437-446
pubmed: 33427007
Front Neurosci. 2019 Oct 10;13:1074
pubmed: 31649501
J Psychopharmacol. 2021 Apr;35(4):319-352
pubmed: 33174492
Psychol Med. 1998 Mar;28(2):437-46
pubmed: 9572100
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
Eur J Public Health. 2020 Jun 1;30(3):532-538
pubmed: 32104898
J Psychol. 2011 Jan-Feb;145(1):39-57
pubmed: 21290929
J Psychopharmacol. 2018 Jul;32(7):756-769
pubmed: 29938565
J Contextual Behav Sci. 2020 Jan;15:39-45
pubmed: 32864325
J Psychopharmacol. 2019 Sep;33(9):1088-1101
pubmed: 31084460
J Psychopharmacol. 2020 Sep;34(9):1008-1020
pubmed: 32345112
Ann N Y Acad Sci. 2009 Aug;1172:252-62
pubmed: 19735249
J Psychopharmacol. 2015 Nov;29(11):1182-90
pubmed: 26442957
J Clin Psychol. 2000 Sep;56(9):1207-20
pubmed: 10987692
Drugs (Abingdon Engl). 2021;28(3):215-226
pubmed: 34349358
Neuropharmacology. 2018 Nov;142:116-134
pubmed: 29162429
Psychother Res. 2020 Apr;30(4):520-531
pubmed: 31256713
Neurosci Biobehav Rev. 2020 Jun;113:179-189
pubmed: 32194129
J Med Internet Res. 2021 Jul 28;23(7):e25973
pubmed: 34319246
J Psychopharmacol. 2019 Sep;33(9):1076-1087
pubmed: 31294673
Acta Psychiatr Scand. 2018 Nov;138(5):368-378
pubmed: 29923178
J Psychoactive Drugs. 2020 Apr-Jun;52(2):101-112
pubmed: 31648596
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Schizophr Res. 2015 Mar;162(1-3):234-47
pubmed: 25631453
J Psychother Pract Res. 1996 Spring;5(2):122-31
pubmed: 22700272
Acta Psychiatr Scand. 2021 Feb;143(2):101-118
pubmed: 33125716
J Consult Clin Psychol. 2010 Jun;78(3):438-48
pubmed: 20515219
J Am Psychoanal Assoc. 2004 Winter;52(1):189-207
pubmed: 15089020
Curr Top Behav Neurosci. 2018;36:393-430
pubmed: 28401522
Conscious Cogn. 2016 Jan;39:28-37
pubmed: 26675408
Drug Test Anal. 2012 Jul-Aug;4(7-8):543-55
pubmed: 22761106
Int J Psychophysiol. 2013 Sep;89(3):305-13
pubmed: 23797150
J Sci Study Relig. 2012 Dec;51(4):721-737
pubmed: 23316089
Health Qual Life Outcomes. 2012 Dec 27;10:156
pubmed: 23270465
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
Psychiatr Q. 2017 Mar;88(1):47-53
pubmed: 27012230
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
J Clin Psychol. 2004 May;60(5):453-60
pubmed: 15048692
Front Pharmacol. 2018 Nov 02;9:897
pubmed: 30450045
J Psychoactive Drugs. 2014 Nov-Dec;46(5):393-5
pubmed: 25364991
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113
pubmed: 28443617
J Psychopharmacol. 2016 Dec;30(12):1279-1295
pubmed: 27856683
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):323-30
pubmed: 20015461
J Psychopharmacol. 2011 Nov;25(11):1453-61
pubmed: 21956378
Psychiatry Res. 2005 Sep 15;136(2-3):223-31
pubmed: 16125785
Front Psychiatry. 2020 Jan 22;10:955
pubmed: 32038317
Am J Psychiatry. 2018 Oct 1;175(10):961-969
pubmed: 30068262
Int J Neuropsychiatry. 1966 Jun;2(3):241-54
pubmed: 5961962
Multivariate Behav Res. 1966 Apr 1;1(2):245-76
pubmed: 26828106
J Psychopharmacol. 2018 Jan;32(1):49-69
pubmed: 29020861
Br J Psychiatry. 2015 Jun;206(6):461-5
pubmed: 25792696
J Psychol. 2014 Sep-Oct;148(5):505-22
pubmed: 25087316
Curr Opin Psychiatry. 2019 Jan;32(1):16-21
pubmed: 30394903
J Psychopharmacol. 2015 Jan;29(1):57-68
pubmed: 25389218
Psychol Assess. 2018 Dec;30(12):1625-1639
pubmed: 30058824
PLoS One. 2010 Aug 31;5(8):e12412
pubmed: 20824211
Schizophr Res. 2015 Dec;169(1-3):298-302
pubmed: 26481617